Richard Edwards has over a decade of experience in developing radiopharmaceuticals for cancer imaging and therapy.
He completed his PhD in Radiochemistry at Cardiff University, specialising in fluorine-18 radiochemistry, followed by postdoctoral positions at the Institut Européen de Chimie et Biologie, The Institute of Cancer Research, and King’s College London.
He subsequently worked as a Research Fellow at King’s College London, where he led radiochemistry programmes focused on the design and translation of radiopharmaceuticals targeting therapy-resistant cancers.
Richard has extensive expertise in radiochemistry across multiple isotopes, automated radiosynthesis, and GMP process development. His work spans the full translational pathway, from early discovery through to clinically relevant manufacturing and validation, and has resulted in multiple high-impact publications and patented technologies.
He is now Co-Founder and Chief Technology Officer of Nuclide Tx, where he leads radiochemistry, GMP manufacturing, and technical strategy. He is responsible for translating the company’s technology into scalable, clinically deployable solutions and plays a central role in delivering its clinical programmes.
Prior to joining Nuclide Tx, Richard initiated and led theranostic programmes that secured over £1.6M in funding and resulted in successful licensing agreements, demonstrating his ability to translate scientific innovation into clinically and commercially viable assets.
